Covaxin Found To Be 77.8% Effective Against Covid In Lancet Study

  • 1:20
  • Published On: November 12, 2021
Cinema View
Embed
Covaxin, a vaccine developed by government's medical research agency and Bharat Biotech International Ltd., was found to have a 77.8% efficacy rate against symptomatic Covid-19 in a long-awaited analysis published in The Lancet.

Related Videos

"A Very Big Source Of Covid Vaccines For World": Bill Gates Praises India
February 29, 2024 3:21
Bharat Biotech's Suchitra Ella On The Lessons From The Covid-19 Pandemic
April 14, 2023 8:47
World's 1st Covid Nasal Vaccine Out On Republic Day
January 26, 2023 8:39
India Gets Its Own Nasal Vaccine, Booster Costs Rs. 800 Per Dose
January 26, 2023 1:18
Covid Nasal Vaccine: Everything You Need To Know
December 27, 2022 1:18
Centre, States To Work In "Collaborative Spirit" To Fight Covid: Health Minister
December 23, 2022 2:57
Nasal Vaccine From Today, Hospital Drills - Preps In Top Gear
December 23, 2022 2:16
Bharat Biotech's Nasal Vaccine Against Covid-19 Cleared For Use
September 06, 2022 2:57
Free Covid Booster Dose For All Adults From Friday For The Next 75 Days
July 13, 2022 1:05
Jabs Begin For 4.7 Crore Children Between 12 And 14
March 16, 2022 3:42
Vaccines For 12-14 Age Group From Wednesday, Boosters For All Above 60
March 14, 2022 1:20
Covaxin Maker Bharat Biotech's Nasal Booster Dose Trials Get Approval
January 28, 2022 2:00
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination